Symbol="OCX"
AssetType="Common Stock"
Name="OncoCyte Corp"
Description="OncoCyte Corporation, a molecular diagnostics company, researches, develops, and markets proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company is headquartered in Irvine, California."
CIK="1642380"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES"
Address="1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="37183600"
EBITDA="-22905000"
PERatio="None"
PEGRatio="0"
BookValue="0.318"
DividendPerShare="0"
DividendYield="0"
EPS="-0.09"
RevenuePerShareTTM="0.007"
ProfitMargin="0"
OperatingMarginTTM="-31.29"
ReturnOnAssetsTTM="-0.149"
ReturnOnEquityTTM="-0.184"
RevenueTTM="875000"
GrossProfitTTM="188000"
DilutedEPSTTM="-0.09"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.218"
AnalystTargetPrice="0.35"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="6.13"
PriceToBookRatio="0.648"
EVToRevenue="2.608"
EVToEBITDA="-0.362"
Beta="1.588"
num_52WeekHigh="1.1"
num_52WeekLow="0.2"
num_50DayMovingAverage="0.234"
num_200DayMovingAverage="0.407"
SharesOutstanding="164821000"
DividendDate="None"
ExDividendDate="None"
symbol="OCX"
open="0.22"
high="0.24"
low="0.21"
price="0.23"
volume="185961.00"
latest_trading_day="2023-07-07"
previous_close="0.21"
change="0.01"
change_percent="4.9302%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="77"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="23"
Volume_recent_avg="413785"
Change_recent_avg="0.01"
Delta_recent_avg="0.03"
Variance_recent_avg="0.02"
Change_ratio_recent_avg="-0.68"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="23"
Aroon_momentum_negative="77"
image_negative_thumbnail_id_1="516"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0089.jpeg"
image_negative_thumbnail_id_2="1126"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0159.jpeg"
image_neutral_thumbnail_id_1="534"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0065.jpeg"
image_neutral_thumbnail_id_2="538"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0061.jpeg"
image_positive_thumbnail_id_1="698"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0010.jpeg"
image_positive_thumbnail_id_2="689"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0019.jpeg"
image_professor_thumbnail_id_1="1195"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0029.jpeg"
image_professor_thumbnail_id_2="1194"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0028.jpeg"
